{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:47Z","timestamp":1777934567162,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T00:00:00Z","timestamp":1653782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,3]]},"abstract":"\n Introduction<\/jats:title>\n Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common toxicities associated with chimeric antigen receptor (CAR) T-cell therapy. Severe grade 3 or higher ICANS is less common and requires the use of corticosteroids with or without an Interleukin (IL)-6 receptor antagonist. Although corticosteroids are effective in the management of CRS and ICANS, their impact on CAR T efficacy remains unknown.<\/jats:p>\n <\/jats:sec>\n \n Case report<\/jats:title>\n We present the case of a 65-year-old male who received CAR T-cell therapy with brexucabtagene autoleucel for stage I\/II Mantle Cell Lymphoma (MCL) and achieved complete remission despite receiving a prolonged course of corticosteroids for severe ICANS.<\/jats:p>\n <\/jats:sec>\n \n Management and outcome<\/jats:title>\n The patient received treatment with high-dose corticosteroids, tocilizumab, and anakinra, in addition to multiple antiepileptic agents. Despite a remitting relapsing pattern of ICANS, the patient not only recovered from the life-threatening complication but also achieved a complete remission at three months post CAR T.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n This case describes the successful use of corticosteroids for the management of ICANS in a patient treated with CAR T-cell therapy for MCL.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10781552221104816","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T02:42:23Z","timestamp":1653878543000},"page":"473-476","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Use of long-term corticosteroids in patients treated with CAR T-cell therapy"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-5867","authenticated-orcid":false,"given":"Hamza","family":"Hashmi","sequence":"first","affiliation":[{"name":"Division of Hematology Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"McGann","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian I","family":"Greenwell","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,5,29]]},"reference":[{"key":"bibr1-10781552221104816","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"bibr2-10781552221104816","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-0115(97)01063-X"},{"key":"bibr3-10781552221104816","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"bibr4-10781552221104816","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"bibr5-10781552221104816","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008865"},{"key":"bibr6-10781552221104816","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-887067"},{"key":"bibr7-10781552221104816","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.009"},{"key":"bibr8-10781552221104816","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1704610"},{"key":"bibr9-10781552221104816","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001694"},{"key":"bibr10-10781552221104816","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001114"},{"key":"bibr11-10781552221104816","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123765"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221104816","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221104816","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221104816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:27:06Z","timestamp":1777688826000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221104816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,29]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1177\/10781552221104816"],"URL":"https:\/\/doi.org\/10.1177\/10781552221104816","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,29]]}}}